An observational study in Chronic Pain and Complex Regional Pain Syndrome, sponsored by Ciusss de L'Est de l'Île de Montréal. Completed at 2 sites in Canada. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Ciusss de L'Est de l'Île de Montréal · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 202 studies in Chronic Pain with a site in Canada — 52 open to participants now, 62 under way, 4 of them phase 3. Chronic Pain · Canada.
Among the 202 studies in Chronic Pain with a site in Canada, this one is the 17th largest by enrollment of the 40 observational ones that give a count, is one of 19 that started in 2025, is one of 40 observational ones, and was the 191st registered.
3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.
Browse Chronic Pain studies →52 of the 202 studies in Chronic Pain with a site in Canada are open now. Recruiting first, the newest first:
Ottawa Hospital Research Institute · Sites in Canada
Ages 18+
Laval University · Sites in Canada
Ages 65+
University Health Network, Toronto · Sites in Canada
Ages 18–80
University Health Network, Toronto · Sites in Canada
Ages 18–65
University of Manitoba · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
202 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 21 · Phase 3 15 · Phase 4 8
First in 2004; this study’s year is marked. 19 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 201 is above the median of 120 across 755 observational studies indexed under Chronic Pain.
Median enrollment 49 across the 162 interventional studies, 138 across the 40 observational. Of the 108 that completed or were terminated, 14 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 202 have an industry lead sponsor. The 10 most frequent:
Ciusss de L'Est de l'Île de Montréal is the lead sponsor of 90 studies on the registry; 32 are open to participants now.
Ciusss de L'Est de l'Île de Montréal has 6 studies filed under Chronic Pain — fewer than ten, so there is no comparison to draw.
15 of the studies in Chronic Pain with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05306899Phase 3University Health Network, TorontoMulti-center RCT of IV Ketamine Efficacy and Safety in Chronic Daily Headaches | 2027-02-01 |
| NCT07137845Université de SherbrookeVirtual Reality and Cranial Nerve Non-invasive Neuromodulation to Improve Quality of Life for Veterans | 2026-12 |
| NCT04939623University of CalgaryNovel Use of Probenecid to Alleviate Symptoms of Opioid Withdrawal | 2026-12-31 |
| NCT03675386University Health Network, TorontoReducing Opioid Use for Chronic Pain Patients Following Surgery | 2026-12-31 |
| NCT06518720Centre for Addiction and Mental HealthTreatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND) | 2027-03 |
Add all 15 to your calendar (.ics) → With an account.
Among the 202 studies in Chronic Pain with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This retrospective observational study aims to describe the use and analyze the effectiveness of various analgesic interventions in patients diagnosed with Complex Regional Pain Syndrome (CRPS) at the Pain Management Center of Hôpital Maisonneuve-Rosemont (HMR) between January 2020 and October 2025.
Background:
Complex Regional Pain Syndrome is a chronic pain condition characterized by severe, persistent pain accompanied by sensory, vasomotor, sudomotor, and motor/trophic changes, often following trauma or surgery. Despite established diagnostic criteria (Budapest criteria), its pathophysiology remains poorly understood, and evidence-based treatments are limited. While multidisciplinary functional rehabilitation remains the cornerstone of management, various analgesic interventions are used to facilitate recovery when medications fail to adequately control pain.
Common interventions include:
Although all these techniques are used in clinical practice, their relative efficacy and predictive factors for success remain unknown. Clinicians rely on experience rather than data-driven guidance to select an initial intervention. Identifying factors such as CRPS subtype or symptom duration that predict analgesic response could improve treatment efficiency and functional recovery.
Methods:
This is a retrospective chart review including all adult patients with a CRPS diagnosis established using the Budapest criteria who received at least one eligible analgesic intervention during the study period. Data will be extracted from electronic medical records by the research team. Exclusion criteria include incomplete clinical documentation or missing information regarding the first consultation, intervention type, or analgesic outcome.
Collected variables include demographics, medications, CNESST (workers' compensation) status, PTSD diagnosis, trauma type, CRPS characteristics (affected limb, type, subtype, symptom duration), details of the first intervention (technique, dose, use of adjuvants), analgesic response, and adverse effects.
STUDY MODEL Retrospective observational study in the form of a chart review. STUDIED POPULATION AND PERIOD Patients followed at the Maisonneuve-Rosemont Hospital Pain Management Center (PMC) for complex regional pain syndrome (CRPS) who received at least one analgesic intervention between January 1, 2020 and October 2025.
This period was chosen to obtain a sufficient number of patients and to best reflect current practice.
SAMPLE SIZE A sample size calculation will not be performed for this study. The PMC is a tertiary pain clinic that treats a large number of patients, and it is estimated that the chosen period will yield a sample of approximately 200 patients.
GENERAL PROCEDURE Data will be collected from digitized records in the Clinibase and Oacis clinical applications.
An initial sampling of charts will be performed in Clinibase by the planning, programming, and research department of the CIUSSS de l'Est-de-l'Île-de-Montréal. A search of the Clinibase database using the type of appointment at the Pain Management Center between January 1, 2020, and October 23, 2025, will provide the chart numbers of potentially eligible patients. The appointment types searched will include: block, ketamine infusion, pamidronate, stellate block, and lumbar sympathetic block.
Each chart will then be reviewed in Oacis to locate the first consultation note at the Pain Management Center in order to verify inclusion criteria-specifically, a diagnosis of complex regional pain syndrome as determined by the Budapest criteria. The use of an eligible analgesic intervention (plexus block, pamidronate infusion, ketamine infusion, stellate or lumbar sympathetic block) for the treatment of CRPS pain will be confirmed. The analgesic technique does not necessarily need to have been performed at the first visit to be eligible. Charts meeting the inclusion criteria will be retained for the research project and analyzed in more detail to collect the required data.
DATA COLLECTION
Patient data:
Demographic data
CRPS data:
Symptoms reported by the patient:
Signs observed by the physician:
CRPS subtype, as determined by the main symptom reported at the first consultation:
First intervention performed:
Plexus block
Sympathetic block
Ketamine infusion
Follow-up visit data:
Data from other follow-up visits:
To better compare the different techniques, a propensity score approach will be used. The probability of receiving each treatment will be calculated based on the following characteristics: age, sex, symptom duration, limb type, CNESST affiliation, medications used, treating physician, and CRPS subgroup. These probabilities will be calculated using multinomial logistic regression and will define the propensity scores. Each patient's characteristics will be weighted using the Inverse Probability of Treatment Weighting (IPTW) method. After weighting, group balance will be verified by ensuring that standardized mean differences (SMD) for each covariate are below 0.1. Finally, the weighted success rate for each technique will be calculated. Weighted Odds Ratios (OR) with 95% confidence intervals will also be computed using weighted logistic regression for each treatment compared to the reference treatment. Sensitivity analyses will be performed using other weighting methods such as Overlap Weighting, 1:1 Matching, and Entropy Balancing.
To identify the best treatment for each subgroup, the probability of success as a function of treatment, subgroup, and a "treatment × subgroup" interaction term will be calculated using logistic regression. If the interaction term is significantly associated with the probability of success, stratified analyses will be conducted by subgroup. For each subgroup, a propensity score will be calculated using the same method described above, excluding the subgroup variable from adjustment. Weighted success probabilities will be calculated for each treatment and each subgroup, as well as ORs with 95% CIs compared to the reference treatment, to identify the optimal treatment for each subgroup.
Adult patients treated at HMR's Pain management centre for CRPS between January 1st 2020 and October 2025.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patient's treated at Maisonneuve-Rosemont Hospital Pain Management Centre for complex regional pain syndrome between January 2020 and October 2025 who received at least one eligible analgesic intervention (plexus or peripheral nerve block, sympathetic block, IV Ketamine infusion, IV Pamidronate infusion)
Frequency distribution of first-line analgesic interventions
To determine the frequency distribution of first-line analgesic interventions used in patients with complex regional pain syndrome
Time frame: within 6 months of first visit at the Pain Clinic
Plan to share: No
No publications or documents are linked to this record.
Ran from Nov 2025 to primary completion in May 2026, 5 months.
Primary completion moved once since we started tracking on Sep 25, 2026: Jun 2026 → May 2026, on Oct 8, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ciusss de L'Est de l'Île de Montréal